CDKN2A and non-small cell lung carcinoma: In addition, meta-analysis of 4 publications comprising 311 patients demonstrated the significant association of p16 hypermethylation and DFS of NSCLC patients (HR 2.04, 95% CI: 1.19–3.50) in a random-effects model (Figure 2B).